{"doi":"10.2217/fmb-2020-0104","title":"Fidaxomicin for the Treatment of\n            <i>Clostridioides Difficile</i>\n            in Children","abstract":null,"journal":"Future Microbiology","year":2020,"id":614449,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1583347,"name":"Tonya Scardina","orcid":null,"position":1,"is_corresponding":false},{"id":388586,"name":"Larry K. Kociolek","orcid":"0000-0002-8756-3417","position":2,"is_corresponding":false},{"id":615365,"name":"Andrew M Skinner","orcid":"0000-0001-9452-9316","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Fidaxomicin for the Treatment of\n            <i>Clostridioides Difficile</i>\n            in Children","abstract":"Fidaxomicin is an oral narrow-spectrum novel 18-membered macrocyclic antibiotic that was initially approved in 2011 by the US FDA for the treatment of Clostridioides difficile infections (CDI) in adults. In February 2020, the FDA approved fidaxomicin for the treatment of CDI in children age >6 months. In adults, fidaxomicin is as efficacious as vancomycin in treating CDI and reduces the risk of recurrent CDI. An investigator-blinded, randomized, multicenter, multinational clinical trial comparing the efficacy and safety of fidaxomicin with vancomycin in children was recently published confirming similar findings as previously reported in adults. Fidaxomicin is the first FDA-approved treatment for CDI in children and offers a promising option for reducing recurrent CDI in this population.","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32715754","pmcid":"PMC8097504","openalex_id":"https://openalex.org/W3045546171","authors":[],"funders":[{"funder_name":"the National Institute of Allergy and Infectious Diseases","grant_id":"K23AI123525, R21AI144549, and R03AI149000","title":null},{"funder_name":"NIAID NIH HHS","grant_id":"K23 AI123525","title":null},{"funder_name":"NIAID NIH HHS","grant_id":"R03 AI149000","title":null},{"funder_name":"NIAID NIH HHS","grant_id":"R21 AI144549","title":null},{"funder_name":"National Institutes of Health","grant_id":"5K23AI123525-04","title":"Optimizing the diagnosis of pediatric Clostridium difficile infection"},{"funder_name":"National Institutes of Health","grant_id":"1R03AI149000-01A1","title":"Identifying the Breadth of Antibody Responses to Clostridioides difficile Infection"},{"funder_name":"National Institutes of Health","grant_id":"5R21AI144549-02","title":"Clostridium innocuum as an emerging multidrug-resistant antibiotic-associated diarrheal pathogen"},{"funder_name":"Merck","grant_id":"","title":null}],"total_grants":8,"fwci":0.0,"citation_percentile":0.05790061,"influential_citations":1,"citation_trend":[{"year":2024,"count":2},{"year":2025,"count":3}],"oa_status":"green","license":null,"oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8097504","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097504","host_type":"GREEN"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8097504","host_type":"repository"},{"url":"https://www.tandfonline.com/doi/pdf/10.2217/fmb-2020-0104","host_type":"publisher"},{"url":"https://doi.org/10.2217/fmb-2020-0104","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32715754","host_type":"repository"},{"url":"https://dx.doi.org/10.2217/fmb-2020-0104","host_type":""}],"fields_of_study":["Clostridium difficile and Clostridium perfringens research","Helicobacter pylori-related gastroenterology studies","Microscopic Colitis","Medicine","0301 basic medicine","0303 health sciences","03 medical and health sciences"],"mesh_terms":["Fidaxomicin","Anti-Bacterial Agents","Clinical Trials as Topic","Clostridium Infections","Humans","United States","Clostridioides difficile","Treatment Outcome"],"keywords":["Fidaxomicin","Medicine","Clostridioides","Vancomycin","Population","Clinical trial","Internal medicine","Pediatrics","Environmental health","Infection","Antibiotics","Gram-positive bacteria","Gastrointestinal Infections","C. Difficile","Pharmacokinetics/pharmacodynamics","Infectious Disease Therapeutics","Clostridioides Difficile","Clinical Trials as Topic","Treatment Outcome","Clostridium Infections","Humans","United States","Anti-Bacterial Agents"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T13:31:52.537491Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}